BBOT vs OKUR
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. OKUR: OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular anomalies while sparing healthy tissue.
Side-by-side fundamentals
| Metric | BBOT | OKUR | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $8.72 | $4.22 | |
| Market cap as of 2026-07-24 | $713M | $175M | |
| P/E as of 2026-07-24 | 151.13 | n/a | |
| ROE as of 2026-07-24 | +2.5% | -61.0% | BBOT higher |
| ROA as of 2026-07-24 | +2.4% | -56.0% | BBOT higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-24 | 0.82 | 0.23 | |
| 1-year return as of 2026-07-23 close | -17.2% | +92.9% | OKUR higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.